Bull&Bear | Metagenomi Surges 125%, Equity Commonwealth Plummets 93% Amid Market Volatility

Mover TrackerMonday, Dec 9, 2024 5:00 pm ET

1min read

In the realm of bullish stocks, Metagenomi (MGX) experienced a significant surge, climbing by 125.41% and maintaining a two-day upward streak. The company has projected that its current cash flow is adequate to sustain its operational plans until 2027.

Zeo Energy (ZEO) also saw a substantial increase of 96.30% over two days. This rise was notably influenced by a report filed on Friday, which disclosed a 58.2% stake in Zeo Energy by a major investment firm.

Quantum-Si (QSI) saw its stock price jump by 49.62%, continuing a two-day rally that totaled a 65.83% increase. The company has recently secured a U.S. patent for "Integrated circuits with sequentially coupled charge storage and related technologies."

Procaps (PROC) recorded a 49.01% rise, showing a two-day increase of 51.52%. The group entered into a secured convertible note subscription agreement with a pharmaceutical holding company on November 29.

The RealReal (REAL) advanced by 39.13%, marking a two-day gain of 46.41%. This increase followed an upgrade by a financial institution, which raised its rating to 'overweight.' The bank suggested that due to structural changes, The RealReal's stock might double, prompting a rise in target price from $4.00 to $15.00 per share.

On the bearish side, Equity Commonwealth (EQC) saw a massive drop of 92.64%. The company announced an initial cash liquidation distribution of $19.00 per common share and set the ex-dividend date.

BioAge Labs (BIOA) experienced a steep decline of 76.85% after an investment firm downgraded its rating from ‘buy’ to ‘hold,’ and another firm revised its rating from ‘buy’ to ‘neutral.’ Both firms lowered BioAge Labs' target price to $7.

Graphjet (GTI) fell by 25.63%, following the sale of shares valued at $281,460 by company insiders, as revealed in recent SEC filings.

Agios Pharmaceuticals (AGIO) witnessed a significant drop of 21.09%, setting a historical record for the decrease in its stock value.

Lastly, Revance Therapeutics (RVNC) declined by 20.68%, continuing a three-day downward trend that accumulated to a 27.34% decrease. This downturn was attributed to a reduction of the acquisition price by 53% by Crown Labs.

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.